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Abstract
Purpose—Cancer cells have altered metabolism, with increased glucose uptake, glycolysis, and
biomass production. This study performed genomic and metabolomic analyses to elucidate how
tumor and stromal genomic characteristics influence tumor metabolism.
Experimental Design—Thirty-three breast tumors and six normal breast tissues were analyzed
by gene expression microarray and by mass spectrometry for metabolites. Gene expression data
and clinical characteristics were evaluated in association with metabolic phenotype. To evaluate
the role of stromal interactions in altered metabolism, cocultures were performed using breast
cancer cells and primary cancer-associated fibroblasts (CAFs).
Results—Across all metabolites, unsupervised clustering resulted in two main sample clusters.
Normal breast tissue and a subset of tumors with less aggressive clinical characteristics had lower
levels of nucleic and amino acids and glycolysis byproducts, while more aggressive tumors had
higher levels of these Warburg-associated metabolites. While tumor intrinsic subtype did not
predict metabolic phenotype, metabolic cluster was significantly associated with expression of a
wound response signature. In cocultures, CAFs from basal-like breast cancers increased glucose
up take and basal-like epithelial cells increased glucose oxidation and glycogen synthesis,
suggesting interplay of stromal and epithelial phenotypes on metabolism. Cytokine arrays
identified hepatocyte growth factor (HGF) as a potential mediator of stromal-epithelial interaction,
and antibody neutralization of HGF resulted in reduced expression of glucose transporter 1
(GLUT1) and decreased glucose uptake by epithelium.
Conclusions—Both tumor/epithelial and stromal characteristics play important roles in
metabolism. Warburg-like metabolism is influenced by changes in stromal-epithelial interactions,
including altered expression of HGF/Met pathway and GLUT1 expression.
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Introduction
Highly proliferative tumor cells undergo fundamental changes in metabolism and nutrient
usage to survive and progress (1), and metabolic transformation appears to be necessary for
sustained proliferation (2). Much of the metabolic transformation is glucose-dependent, with
invasive cancers exhibiting increased aerobic glycolysis (3) via the “Warburg Effect”(4).
The Warburg effect occurs when there is a metabolic shift towards glycolysis, with
increased cellular production of biomass, especially amino acids and nucleic acids. While
the Warburg phenomenon has been investigated for over 85 years, the metabolic interactions
between stroma and epithelium are not well characterized, despite the important role of
stroma in breast cancer biology (5-12).
The gap in our understanding of stromal-epithelial interactions was recently illuminated
when it was shown that epithelial tumor cells induce oxidative stress in the normal stroma
(9), in turn leading to activation of NFκB and HIF-1α pathways in cancer-associated
fibroblasts (CAFs) (11). Concomitant changes in inflammation, autophagy, mitophagy, and
aerobic glycolysis are induced in the stroma, which then produces energy-rich metabolites
(such as lactate and pyruvate) that are secreted and used by epithelial cells to generate ATP
(11, 13). This bidirectional communication, with aerobic glycolysis in stroma fueling cancer
growth is referred to as “Reverse Warburg Effect” (14-16), and its discovery established an
important role for stroma in altering metabolism (9-11). However, differences in
metabolomics by stromal-epithelial interaction and according to breast cancer subtype have
not been widely investigated.
Breast tumors show substantial heterogeneity (17) with at least five distinct subtypes:
luminal A, luminal B, HER2-positive, basal-like, and claudin low breast cancers (18-20). In
addition to their unique cell-autonomous characteristics [including unique mutation patterns,
chemotherapy responses, and cellular phenotypes (21-23)], these subtypes have distinct
interactions with the stroma. The interaction of basal-like breast cancer cells with fibroblasts
leads to an increase in inflammatory cytokines and migratory behavior, while luminal cells
in culture with fibroblasts demonstrate distinct gene expression and altered proliferation (12,
24). This evidence of subtype-specific interactions with surrounding stroma underscores the
importance of studying epithelial and stromal factors simultaneously when evaluating tumor
metabolism.
In the present study, we apply metabolomics and radiotracer metabolic studies to
simultaneously investigate the role of tumor gene expression and stromal-epithelial
interactions in tumor metabolism. Tissue samples were used to perform gene expression and
samples were classified using multiple published signatures: the PAM50 signature, claudin
low signature, and in vivo wound response signature (17, 20, 25). These gene expression
phenotypes were then compared with metabolomics classes identified by analysis of 379
metabolites. Complementary coculture experiments were performed to evaluate subtype-
specific metabolic interactions of stromal and epithelial cells experimentally. Our results
illustrate that compared to luminal cancer cells or luminal-derived cancer associated
fibroblasts (CAFs), basal-like cells and basal-like CAFs play a strong role in determining
substrate metabolism in culture. Strong associations between tissue metabolic phenotype and
tissue gene expression also suggest the importance of stroma in metabolic cancer
microenvironments.
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31 fresh frozen breast tumor samples, 6 breast tissue samples from reduction mammoplasty,
and 5 metastatic samples were obtained under IRB-approved protocols at the University of
North Carolina at Chapel Hill (UNC-CH). Patients were treated according to the standard of
care dictated by disease stage, ER, and HER2 status. Table 1 describes patient demographics
and tumor characteristics. All tissues were handled by snap freezing immediately after
surgery, and RNA was isolated using a protocol as described by Hu et al. (26). RNA
integrity was determined using the RNA 6000 Nano LabChip Kit and Agilent 2100
Bioanalyzer.
Microarrays
Microarrays experiments were performed as described (26). Briefly, labeled cRNA was
generated using Agilent's Low RNA Input Linear Amplification Kit. Cy5-labeled
experiment samples were combined with Cy3-labeled reference (Stratagene Universal
Human Reference spiked with 1:1,000 with MCF-7 RNA and 1:1,000 with ME16C RNA to
increase expression of breast cancer genes) and hybridized to 4×44K Agilent whole genome
arrays or 244K Agilent custom arrays. For two cases with duplicate arrays, the intraclass
correlation coefficients (ICC) were 0.597 and 0.886, suggesting moderate to strong
agreement between replicates. All tumor gene expression data are publicly available through
the Gene Expression Omnibus (GSE6128 and GSE6130).
Metabolite arrays
For each tumor, a single sample was analyzed for metabolites. Tissue (100 mg) was
homogenized in a volume of water at 4 μL per mg of sample in a 2 mL cryovial with two
3mm Zirconium oxide beads, one 3/8 steel ballcone and one 1/8 steel ballcone on the
GenoGrinder at 1000 strokes/minute for five minutes. A 100 μL aliquot of the homogenate
was placed in a 96-well deepwell plate along with two 3mm Zirconium oxide grinding beads
per well. The plate was placed in the chiller on the robot and a 400 μL volume of EtOAc/
EtOH (1:1) with 2.5 μg/mL 2-fluorophenylglycine and 25 μg/mL d2-maleic acid and
tridecanoic acid was added to each well. The plate was capped with a plate mat and samples
were shaken on GenoGrinder at 675 strokes/ minute for two minutes. The plate was
centrifuged on a Beckman GS-6R centrifuge at 3200 RPM for 5 minutes at 4°C then placed
back on the Hamilton LabStar robot and the centrifugates were transferred to a second plate.
A 200μL volume of MeOH was placed in each well of the first plate and the plate was
shaken and centrifuged as before. The centrifugates were transferred as before and the same
process was repeated using 200uL volume of MeOH/H2O (3:1) and then repeated using
200uL volume of DCM/MeOH (1:1). The samples were mixed by pipetting up and down
several times and a 225 μL aliquot of each was transferred to each of two 250 μL
autosampler vial inserts. All extracts were placed in the Zymark Turbo Vap 96 for
concentration under nitrogen streams for 25 minutes. A second 225 μL aliquot of each
sample was transferred to the appropriate insert and the samples were placed in the
Labconco Centrivap Concentrator for drying for 6.5 hours for drying. Samples were
transferred to the Labconco Freezone 6 lyophilizer for further overnight drying. For LC/MS,
a 40 μl volume of MeOH with 20 μg/mL D10-benzophenone was added to each sample.
Samples were shaken with a Lab-Line Titer plate shaker for 5 minutes on setting 7 then a 60
μL volume of 0.1% formic acid was added containing 5 μg/mL d3 leucine, 5 μg/mL DL-4-
chlorophenylalanine, 5 μg/mL 4-bromo-DL-phenylalanine and 0.5μg/mL amitryptyline.
For GC/MS, samples were derivatized to a final volume of 50 μl for GC/MS analysis using
equal parts bistrimethyl-silyl-trifluoroacetamide and solvent mixture
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acetonitrile:dichloromethane:cyclohexane (5:4:1) with 5% triethylamine at 60°C for one
hour. Three types of controls were analyzed in concert with the experimental samples:
samples generated from pooled experimental samples served as technical replicates
throughout the data set, extracted water samples served as process blanks, and a cocktail of
standards spiked into every analyzed sample allowed instrument performance monitoring.
Experimental samples and controls were randomized across the platform run. Raw data is
included as a supplemental table (Table S1).
Metabolite data analysis
Metabolite levels with signal intensity greater than 10 dpi in both channels and at least 80%
present data were selected and the red/green Lowess normalized ratios for each gene were
log2 transformed. Missing data were imputed using k-nearest neighbors' imputation (with
k=10). This resulted in a complete dataset consisting of 379 metabolites and each row/
metabolite was median centered. Data were analyzed by unsupervised Significance Analysis
of Microarray (SAM) (27) and significant metabolites were clustered across all samples
using average-linkage hierarchical cluster analysis, results were visualized using Java
Treeview (28). SAM uses the variance structure of the data to compute expected
distributions. Small fold changes were statistically significant by SAM analysis due to low
variation between samples within a class. To test whether there was a significant trend in
metabolite level for classes of metabolites [amino acids, carbohydrates/sugars, nucleic acids,
and the tricarboxylic acid (TCA) cycle metabolites], we estimated the β-value and p-value
corresponding to linear regression of metabolite level on an ordinal variable equal to 1 for
normal tissue, 2 for Cluster 1 samples, 3 for Cluster 2 samples, and 4 for metastases.
Statistical tests of the trend were two-tailed and standard error was calculated (SAS version
9.2). Because these clusters emerged from SAM analyses where multiple comparisons were
adjusted, no adjustment for multiple comparisons was made in the trend analyses. The
objective of these analyses is to show whether there is evidence of a monotonic increase or
decrease in metabolite level.
Gene Expression Data Analysis
Using the probe set common to both array platforms (25), probes with signal intensity
greater than 10 dpi in both channels and at least 80% present data were selected and the red/
green Lowess normalized ratios for each gene were log2 transformed. Duplicate microarrays
corresponding to the same patient sample were combined by averaging. Missing data were
imputed using k-nearest neighbors' imputation (with k=10). Gene annotations from each
dataset were mapped to UniGene Cluster IDs (UCIDs, Build 161) using the SOURCE
database, and multiple occurrences of a UCID were collapsed by taking the median value for
that ID within each experiment and platform. This resulted in a complete dataset consisting
of ∼2800 genes, and each experiment was standardized to N(0,1) and each row/gene was
median centered.
To identify genes that significantly changed by metabolic cluster (Cluster 1 or Cluster 2)
data were analyzed by two-class Significance Analysis of Microarray (27). Significant genes
were clustered across all samples using average-linkage hierarchical cluster analysis and
results were visualized using Java Treeview (28). Significant genes were evaluated for
ontological enrichment using Ingenuity Pathway Analysis (IPA), with Benjamini–Hochberg
(B-H) multiple testing correction. Significant functions and pathways were defined as those
with B-H p-values less than 0.05.
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Associations between metabolic phenotype and biologically-defined gene expression
signatures
To characterize the biological phenotypes of the metabolic clusters, gene expression in each
sample was compared to an existing in vivo breast-derived wound response signature (25).
The wound response signature was generated by comparing cancer-adjacent stroma-rich
breast tissue to breast tissue from reduction mammoplasty, which identified an active wound
signature in the cancer-adjacent tissue. The median centered gene expression profile of each
patient was evaluated for correlation with this signature by calculating Pearson correlation
coefficients, using the method of Creighton et al. (29). Briefly, vectors corresponding to the
genes in the wound response signature were constructed, with 1 assigned to up-regulated
genes and -1 assigned to down-regulated genes. Sample arrays were filtered to retain only
genes with interquartile range (IQR) of at least 0.8. A Pearson correlation coefficient was
calculated comparing this standard vector to the vector of median centered gene expression
for each patient. Patients were classified as positive if the Pearson correlation coefficient
was greater than zero, and negative if the coefficient was less than zero. The association
between metabolic cluster and wound response score was evaluated using a two-tailed,
Fisher's exact test (performed in SAS version 9.2).
Cell culture
Primary CAFs were isolated from breast tissue of patients undergoing breast surgery for
primary invasive breast carcinoma at UNC Hospital. Tissue specimens were procured under
an IRB-approved protocol (LCC 0913) by the Lineberger Cancer Center Tissue Procurement
Facility and stored in 10 mL of DMEM/F12 with 10% FBS on ice until processing (up to 6
hours). Tissue was minced and transferred to a 15 mL conical tube with 9 mL of suspension
media: DMEM/F12 (GIBCO) supplemented with 10% FBS (GIBCO), 1% Pen/Strep
(Invitrogen), 2.5 ug/mL Amphotericin B solution (Invitrogen), 300 U/mL collagenase
(Sigma) and 100 U/ml hyaluronidas (Sigma). Collagenase digestion occurred overnight at
37°C and the sample was then centrifuged for 30 seconds at 100 × g. A top layer of
hydrolyzed fat was discarded and supernatant was centrifuged at 200 × g for 3 minutes.
Supernatant was transferred to a new tube and centrifuged at 400 × g for 5 min. The
supernatant was discarded, and the remaining fibroblast pellet was resuspended in 7mL of
suspension media, as described above, and transferred to a T25 flask. Cells were grown at
37°C in a 5% CO2, with media changed every 3-5 days and split into a T75 at 80%
confluency.
SUM149 (basal-like) and MCF7 (luminal) breast cancer cell lines were obtained from
ATCC (30). Cell lines were maintained 37°C and 5% CO2 in DMEM/F12 supplemented
with 10% FBS and 50 units/mL Penicillin/Streptomycin. Cell lines were tested for
mycoplasma by the Tissue Culture Facility at Lineberger Cancer Center.
Cocultures
Two types of cocultures were performed to model the tumor metabolic microenvironment.
First, we performed direct cocultures, defined as a coculture where the two cell types are
grown in physical contact, in the same well. Direct cocultures were used for all of the
glucose assays plated at a physiologically relevant 1:2 ratio of cancer cells to fibroblasts in
24-well plates and were maintained for 96 hours, changing the media at 48 hours, before
assays were performed. Second, we performed indirect cocultures or transwell cultures,
where fibroblasts and cancer cells are grown separated by a membrane but in contact via
soluble factors. Indirect cocultures were solely used to calculate individual cell growth rates
for interacting stromal and epithelial cells. These studies were performed by seeding one of
the two cell types on the insert layer of Corning Transwell plates with 0.4-mm pore
polycarbonate membranes whereas the other cell type was grown in the bottom of the well.
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At 96 hours, 48 hours after media change, cells were harvested from top and bottom wells
and counted using a Coulter Counter (Beckman Coulter, Inc.) to determine the ratio of cells.
Identical starting stromal-epithelial ratios and analysis time points were used for both direct
and indirect cultures. Two luminal and one basal-like primary CAF cell lines were used for
all in vitro experiments and all experiments were repeated in triplicate. For HGF inhibition,
cells were treated with 0.5μg/mL of anti-HGF antibody (Abcam) at time of plating, and
media was not changed during the course of the experiment (48 hours).
Glucose uptake assay
Cells were plated for direct coculture at 1.0 × 105 epithelial cells/well and 2.0 × 105
fibroblasts/well into 24 well plates and allowed to grow for 96 hours, with media changed at
48 hours. Cells that were treated with anti-HGF antibody or sham were assayed at 48 hours.
The cells were washed twice with 0.5 ml 37°C 1× PBS and then incubated for 10 minutes at
37°C in 0.5 ml/well KRH buffer (136 mM NaCl, 4.7 mM KCl, 1.25 mM CaCl2, 1.25 mM
MgSO4, 10 mM HEPES, pH 7.4) with 0.5 μCi/ml [3H]2-Deoxy-D-glucose (PerkinElmer,
Waltham, MA). Cells were washed twice with 0.5 ml iced 1× PBS with 20 mM D-glucose
and then lysed in 0.5 ml lysis buffer (0.025% SDS, 1% TX-100 in 1× PBS). Lysates were
centrifuged at 20,000 × g for 5 minutes at 4°C and the protein concentration was determined
with a Bicinchoninic Acid (BCA) assay (Thermo Fisher Scientific). The rest of the lysate
was then added to a scintillation vial filled with 4.5 ml EcoScint H (National Diagnostics,
Atlanta, GA) for scintillation counting. Because cell composition changes during the time of
coculture (due to different growth rates for cancer cells and fibroblasts), expected metabolic
responses for cocultures was computed using cell numbers at time of measurement and
using measured activity levels. For each of n cocultures, the following formula was used to
calculate expected metabolic activity level:
Where m = metabolic activity and a = fraction of epithelial cells as estimated by cell counts
for both cell types at a given time point after the start of coculture. Expected activity
computed by this formula was compared to observed activity, and fold change was
computed as a function of expected over observed metabolic activity. Statistical analyses of
these data were performed with two-tailed t-tests (e.g. all MCF7 cocultures vs. all SUM149
cocultures, or all LCAF cocultures vs. BCAF cocultures, etc.).
Glucose oxidation/glycogen synthesis
Cells were plated for direct coculture at 1.0 × 105 epithelial cells/well and 2.0 × 105
fibroblasts/well into 24 well plates and allowed to grow for 96 hours, with media changed at
48 hours. The cells were washed twice with 0.5 ml 37°C 1× PBS and then incubated for 120
minutes at 37°C in 0.5 ml/well KRH buffer (136 mM NaCl, 4.7 mM KCl, 1.25 mM CaCl2,
1.25 mM MgSO4, 10 mM HEPES, pH 7.4) with 2 μCi/ml [14C] uniformly labeled D-
glucose (PerkinElmer). Following incubation, 400 μl of KRH media from each well was
placed into the upper well of an oxidation plate with 200 μl 1M NaOH in the lower well.
The oxidation plate was sealed with a gasket and lid and the media well acidified by
injecting 100 μl 70% perchloric acid. The oxidation plate was placed on an orbital shaker
for 1 hour and then 150 μl of the NaOH from each well was placed into a scintillation tube
with 4.5 ml EcoScint H for scintillation counting. The data are expressed as DPM/mg of
protein/minute. Cells from this assay were washed twice with 0.5 ml iced 1× PBS with 20
mM D-glucose and then lysed in 0.5 ml lysis buffer (30% KOH saturated with Na2SO4).
Lysates were heated to 95°C for 10 minutes and centrifuged at 20,000 × g for 5 minutes at
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4°C. The protein concentration was determined with a BCA assay (Thermo Fisher
Scientific). To the remaining lysate, an equal volume of 100% ethanol was added to
precipitate glycogen and samples stored at -20°C overnight. Samples were centrifuged at
20,000 × g for 5 minutes at 4°C and the supernatant removed. The pellets were washed in 1
ml of 70% ethanol and centrifuged at 20,000 × g for 5 minutes at 4°C. Supernatants were
removed and pellets air-dried overnight. Pellets were then resuspended in 0.5 ml water and
transferred to a scintillation vial with 4.5 ml EcoScint H for scintillation counting. The data
are expressed as DPM/mg of protein/hr fold change of observed/expected. For each of these
cocultures, the expected activity of glucose oxidation and glycogen synthesis pathways were
computed as described above and used to compute fold change relative to expected.
Statistical analyses of these data were performed as described above for glucose uptake.
Lactate assay
Cells were plated at 1.0 × 105 epithelial cells/well and 2.0 × 105 fibroblasts/well into 24 well
plates and allowed to grow for 48 hours, media was collected and stored in aliquots at -80°C
and assayed for lactate content. Briefly, fresh NAD+ was added to assay buffer (175 mM
Hydrazine Sulfate, 68 mM Glycine, 2.9 mM EDTA, 11.3 mM NAD+, pH 9.5) just prior to
assay. In a 96-well plate, 200 μl of assay buffer and 40 μl of lactate standard or media
sample were combined in each well. The plate was then pre-read at 340 nm followed by the
addition of 1U of lactate dehydrogenase in a 10 μl volume of water. The plate was mixed
and read at 340 nm. The lactate concentration in each sample was determined from the
standard curve. Computed expected levels of lactate were performed as described for other
metabolic assays above. Statistical analyses of these data were performed as described above
for glucose uptake.
Western Blot
Cells were harvested from culture and protein was isolated and quantitated. Lysates were
denatured by boiling with β-mercaptoethanol and 30μg of protein were electrophoresed on a
4–20% Tris-HCl Criterion precast gel (Bio-Rad) and transferred to a Hybond-P membrane
(Amersham Biosciences) by electroblotting. The blots were probed with antibodies against
the GLUT1 (Abcam) and β-actin (Cell signaling). Blots were washed three times with Tris-
buffered saline supplemented with 0.1% TWEEN and then were probed with ECL anti-
mouse IgG horseradish peroxidase-linked whole antibody from rabbit (Amersham-GE
Healthscience). Blots were rewashed, and detection was by enhanced chemiluminescence
western blotting detection system (Amersham-GE Healthcare). Relative GLUT1 protein
concentration was quantified using ImageJ software, pixel intensity was used to measure the
protein band of GLUT1 and divided by the intensity of the β-actin band.
Analysis of cytokine expression in conditioned media
Conditioned media from direct 1:1 cocultures (48hours) was analyzed on a RayBio Human
Cytokine Antibody Array 5 (80) (Raybiotech) designed to detect 80 cytokines and
chemokines. These glass arrays were used according to manufacturer protocol to measure
cytokine and chemokine expression in the conditioned media from direct cocultures. Briefly,
slides were blocked by incubation with blocking buffer at room temperature for 30 min and
incubated with 100 ul of the sample at room temperature for 90min. Membranes were
washed and incubated with biotin-conjugated antibodies overnight at 4°C. Finally, the
membranes were washed and incubated with fluorescent dye-conjugated streptavidin at
room temperature for 2 hours. After final washing, slides were dried by centrifugation at
1000rpm for 3 minutes. Fluorescent signal was detected on a laser scanner using a cy3
(green) channel (excitation frequency 532nm). Data for each cytokine were normalized to
positive controls on the same slide to estimate relative protein expression. Each monoculture
or direct coculture was analyzed in duplicate.
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cDNA Synthesis and qPCR Analysis
RNA was isolated from cultured cells using RNeasy Mini kit (Qiagen) following
manufacturers' instructions. 1μg of total RNA was reverse transcribed into cDNA using
iScript cDNA synthesis kid (Bio-Rad). qPCR was performed with a dilution of cDNA
equivalent to 100ng RNA in 18μl of master mix (10 μl SsoFast 2× Probes Supermix (Bio-
Rad), 0.5 μl 18S-VIC and 0.5 μl gene specific Assay-On-Demand-FAM (Applied
Biosystems), 7 μl water) was used in each well of the qPCR 96-well plate. The following
primer/probe sets (Applied Biosystems) were used: GLUT1, 18S. Amplification conditions
were as follows: 1 cycle of 95°C for 1 minute; 40 cycles of 95°C for 5 seconds, 60°C for 20
seconds. The best linear fit equation generated by the amplicon standard curve was used to
determine the number of copies of GLUT1 in the cDNA generated. Relative transporter
expression was normalized to the expression of 18s. Statistical analyses of these data were
performed with a two-tailed t-test (e.g. cocultures vs. monocultures, or cocultures with and
without HGF antibody).
Results
Evidence of two distinct metabolic clusters
To identify metabolic subgroups of tumors, unsupervised hierarchical clustering was
performed on 379 metabolites across 31 breast tumor and 6 normal breast tissue samples.
Patient characteristics for these 37 patients are described in Table 1. Two main clusters
resulted (dendrogram shown in Figure 1A and heatmap shown in Figure 1C), one of which
(Cluster 1) was primarily normal tissue and less aggressive tumors (90% of luminal A
tumors; 100% of normal breast tissues) (Figure 1B, colored boxes). The other cluster
(Cluster 2) was enriched for more aggressive tumor subtypes and metastatic tumors (60% of
basal-like tumors; 66.7% of luminal B tumors; 100% of metastases). Cluster 2 tumors had
significantly larger tumor size (p=0.047) than those in Cluster 1. While associations were
not statistically significant, Cluster 2 tumors were also substantially more likely to be ER
negative (Figure 1B, gray scale boxes) and have poorly differentiated tumor grade.
Given the importance of stromal cells in altering glucose metabolism of cancer cells in
previous literature (10, 31, 32), we hypothesized that metabolite subtypes would correlate
with stroma-driven gene expression in the human tissue specimens. Using a published
wound response signature identified in cancer-adjacent stroma-rich breast tissue when
compared to breast tissue from reduction mammoplasty (25), we observed an association
between metabolic cluster and wound response, with a higher percentage of tumors in
Cluster 2 (the more aggressive metabolic group) expressing activated wound response
signature (Figure 1D, p=0.054). Of the tumors in Cluster 1, 39% were positively correlated
with the wound response signature, while 79% of tumors in Cluster 2 were positively
correlated with the signature. Interestingly, the association between metabolic subtype and
wound response signature was stronger than the association with either ER status or breast
tumor subtype (Table 1).
Pathway driven metabolic phenotypes in breast tumors
Four well-defined groups of metabolites defined the differences between metabolic clusters:
amino acids, sugars, nucleic acids, and metabolites involved in the tricarboxylic citric acid
(TCA) cycle. Principal Component Analysis (PCA) using metabolites in each of these four
metabolite classes separated the Cluster 1 and 2 tumors and delineated normal from
metastatic samples (Figure 2). The association between metabolite levels and metabolite
cluster was strongest for amino acids (Figure 2A, PC1-85.7%, PC2-4.3%), followed by
nucleic acids (Figure 2B, PC1-51.6%, PC2-24.3%), TCA cycle (Figure 2C, PC1-54.2%,
PC2-17.2%), and carbohydrates/sugars (Figure 2D, PC1-32.8%, PC2-13.6%), suggesting the
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relative importance of these types of metabolites in driving clustering and aggressive tumor
subtype. Considering individual metabolites in each of these four categories, there were 19
amino acids that increased between normal samples and Cluster 1, and between Cluster 1
and non-metastatic tumors in Cluster 2 (Table 2). Many of these metabolites increased
further in metastatic tumors from different sites (skin, lung, liver, or brain). Several
individual metabolites showed a trend from normal to Cluster 1 tumors to Cluster 2non-
metastatic tumors, including glucose (decrease), glucose-6-phosphate (increase), lactate
(increase) and ribulose-5-phosphate (increase). Malic acid and fumaric acid, both
metabolites in the TCA cycle, increased from normal to Cluster 1 tumors to Cluster 2 non-
metastatic tumors, inversely proportional to citric acid levels. In summary, many metabolites
that are crucial for glucose metabolism and the citric acid cycle were present at lower or
higher levels in the more aggressive tumor cluster (Cluster 2) compared to Cluster 1. A
diagram illustrating the pathways affected by this metabolic shift is presented in Figure 3.
Metabolic processes indicate stroma-influenced Warburg Effect
Previous experimental studies focused on specific metabolic hallmarks of Warburg
phenomenon recently identified a ‘Reverse Warburg effect’, where stromal cells act as
important drivers of the metabolic phenotype of cancers (10, 11, 14, 15, 33). Given this
previous literature and the correlation between metabolic phenotype and wound response
genomic signature, we performed cocultures that modeled basal-like and luminal metabolic
microenvironments to assess whether fibroblast characteristics, cancer cell characteristics, or
interactions between the two were important in tumor metabolism. Basal-like
microenvironments were modeled with SUM149 basal-like breast cancer cells and with
basal-like cancer associated fibroblasts (BCAFs). Luminal microenvironments were
modeled with MCF7 luminal breast cancer cells and luminal cancer-associated fibroblasts
(LCAFs). Results demonstrated a complex interplay of stromal and epithelial cells in
determining metabolic phenotype.
Consistent with the observation that more aggressive subtypes have more extreme metabolic
phenotypes, SUM149 (basal-like)cells displayed higher glucose uptake than MCF7
(luminal) cells in monoculture (Supplemental Figure 1A). However SUM149 cells had even
greater glucose uptake when grown with BCAFs (Figure 4A), showing a 2.9-fold increase in
observed relative to expected (p<0.001). BCAFs also increased MCF7 glucose uptake (1.9-
fold higher than expected, p=0.001). In contrast, LCAFs suppressed glucose uptake in
MCF7 cocultures, but had no effect in coculture withSUM149 cells. Overall, BCAF
cocultures had a 2.8 fold increase in glucose uptake when compared to LCAF cocultures
(p=0.04).
Once glucose is taken up, utilization includes glucose oxidation, glycogen synthesis, and
lactate production, which are endpoints of oxidative metabolism, storage, and glycolysis,
respectively. Basal-like cells had higher glucose oxidation in monoculture (Supplemental
Figure 1). However, glucose oxidation was suppressed in all luminal coculture conditions
(MCF7 cells or LCAFs present, Figure 4B). Increased glucose oxidation among SUM149
cells occurred only when these cells were cocultured with BCAFs (2.1-fold higher glucose
oxidation compared to SUM149s with LCAFs, p<0.001). This is interesting, suggesting that
both stromal and epithelial factors contribute to glucose oxidation.
Glucose oxidation in the cell is balanced by non-oxidative glucose utilization, including
glycogen synthesis. Stored cellular glycogen can promote cell survival in conditions of
hypoxia (33). Glycogen synthesis was increased in all cocultures relative to monocultures
(Figure 4C), however the increase in glycogen synthesis was most noticeable among
SUM149 cocultures.
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Finally, we assessed lactate as a measure of anaerobic glycolysis. Lactate production was
higher in basal-like cancer cells and cancer-associated fibroblasts than in luminal cells in
monoculture (Figure S1A), however all coculture models showed about a 1.5-fold higher
than expected lactate production that was not subtype driven (Figure S1B). Considering all
of these metabolites, coculture of basal-like epithelial cells with basal-like fibroblasts
revealed the strongest phenotype of elevated glucose metabolism including glycolysis,
oxidation, and storage.
Glucose uptake regulated by tumor-stromal interactions between GLUT1and HGF
Given the importance of stromal cells in altering glucose metabolism of cancer cells in
previous literature (10, 32, 33) and our coculture data, we hypothesized that the expression
of glucose transporters may be regulated by tumor-stromal interactions. GLUTs 1-4 are
Class I integral membrane proteins responsible for the transport of glucose. We focused on
GLUT1 because it is responsible for basal levels of glucose uptake in all cells and glucose
levels inversely regulate its expression (34). GLUT1 has also been shown to be the
predominant glucose transporter in human breast carcinomas and mouse mammary
carcinomas (35, 36). GLUT1 protein levels were higher in the more aggressive SUM149
monocultures when compared to MCF7 monocultures (Figure 5A). Coculture conditions
further increased GLUT1 protein levels in both cell types, demonstrating a role for stroma in
the regulation of glucose metabolism (Figure 5A). To identify soluble factors and specific
pathways regulating this change in GLUT1, cytokine protein arrays were performed. These
results indicated significantly higher levels of HGF in coculture conditions (Figure 5B).
Consistent with previous data in muscle (37), we hypothesized that HGF was playing a
regulatory role in GLUT1 expression. We were able to completely block GLUT1 RNA
expression by inhibiting HGF levels in the media, confirming our hypothesis (Figure 5C).
To further confirm this mechanism and its downstream effects on metabolism, we compared
levels of glucose uptake in stromal-epithelial cocultures with and without HGF inhibition.
Our results show 65.6% decrease in glucose uptake (p=0.055) with HGF inhibition in
SUM149:RMFcocultures (Figure 5D).
Discussion
Gillies and Gatenby (38) have argued that adaptations to resource scarcity are fundamental
in the evolution of carcinogenesis and have shown a variety of pathways dysregulate aerobic
glycolysis in tumors (39). Consistent with metabolic adaptation during carcinogenesis,
metabolite profiles can distinguish cancer from non-cancer (40). However, while it has been
increasingly recognized that cancers evolve into distinct breast cancer subtypes, few studies
have evaluated evolution of metabolic differences between breast cancer subtypes (39,
41-44). Our study demonstrates that tumors differ from normal samples in their
metabolomic profiles, but extended this to describe metabolomic heterogeneity within
tumors. High resolution quantitative profiling of metabolites from normal and tumor tissue
identified two metabolic subgroups that were associated with aggressive tumor
characteristics. Interestingly, though, these metabolic subtypes did not strongly correlate
with established PAM50 or claudin low tumor gene expression subtypes. While larger
studies are warranted to allow better powered analysis of how intrinsic subtype affects
metabolism, an important next step was to understand whether other genomic signals
correlate with metabolic subgroups.
We hypothesized that interactions between tumor epithelium and stroma can be detected in
genomic data, and that these interactions contribute to the evolution of distinct metabolic
microenvironments. Previous genomic studies have emphasized the importance of host-
tumor interactions in progression (45), suggesting possible pathways to test in association
with metabolomic subtype. From microarray studies, a wound response is tumor promoting
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in the presence of initiated cells (46, 47) and wound response gene signatures are prevalent
in tumor adjacent, stroma-enriched tissue (25). Thus, we tested an in vivo wound response
signature and found its expression to be strongly associated with metabolic subtype. These
results demonstrate that integrated analyses of metabolite and gene expression data can
identify phenotypically distinct groups of breast cancers.
Other recent papers have performed integrated analyses of metabolomics and gene
expression datasets, emphasizing identification of genes associated with individual
metabolite levels or identification of metabolic phenotypes associated with specific tumor
characteristics (48-51). A large study of metabolite profiles across 289 tumor samples
identified groups of tumors corresponding to hormone receptor status and grade, however,
that study did not seek to identify associated genomic changes beyond these tumor
characteristics (49). Borgan et al. analyzed metabolite profiles of 46 mostly luminal A breast
cancers (48) and linked metabolic heterogeneity within the luminal A breast cancers to gene
expression differences, including differences in extra cellular matrix (ECM) genes. Their
observation of the importance of ECM genes in metabolism is consistent with our finding
that metabolism was strongly correlated with stromal signature and stromal-epithelial
interactions. Also consistent with our findings, Borgan et al. noted heterogeneity within the
luminal A subtype, demonstrating that intrinsic subtype alone does not determine metabolic
phenotype (48). In our study, we aimed to include a more diverse sample set with six
different subtypes of breast cancer and an approximately even distribution of ER+ and ER-
tumors. Our power to perform comprehensive assessments of subtype-specific changes was
limited due to sample size, but our results do suggest heterogeneity of response within
classes defined by tumor subtype.
Few integrated, observational studies of gene expression and metabolomics data, including
our own dataset, have been of sufficient size to evaluate both tumor and stromal
characteristics. To address this limitation, we combined our tissue-based observations with
well-established cell culture based models that mimic the tumor interactions with
microenvironment (5) to confirm the pathway changes seen in our gene expression and
metabolomics data. While we were unable to measure all metabolites, we selected the
metabolism of glucose for more focused investigation because it is central to many of the
Warburg-like changes observed in the full metabolic profile. Our results demonstrate that
metabolic phenotype is a complex interplay between tumor characteristics and the
surrounding stromal biology. Basal-like breast cancer epithelial cells more readily take up
glucose from surrounding tissue than luminal breast cancer cells. Furthermore, basal-like
CAFs also stimulate marked increases in glucose uptake, even in luminal breast cancer cells.
Conversely, luminal CAFs produce no change or can slightly decrease glucose uptake and
oxidation in basal-like breast cancer cells. Glucose oxidation depended on both stromal and
epithelial characteristics, while glycogen synthesis appears to be less sensitive to the
differences between luminal CAFs and basal-like CAFs, correlating most strongly with
epithelial cell content. This latter pattern of metabolite production in coculture suggests an
acquired capability – increased glycogen storage in response to micro environmental signals
– and raises the question as to whether increased glycogen synthesis is a hallmark of basal-
like breast cancers.
While primary CAFs used in this study demonstrate that there is interindividual variation in
the effect of CAFs, to establish central trends for basal-like vs. luminal stroma will require
greater numbers of cell lines. However, these results underscore the importance of
understanding variation in tumor stroma. Characteristics of fibroblasts, such as aging or
senescence phenotypes, can also alter metabolism as shown in recent studies (52). Our
results confirm that understanding which metabolites are sensitive to stromal factors and
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which are dominated by epithelial characteristics is necessary if metabolic processes are to
be targeted for cancer treatment or prevention.
Future metabolic-targeted treatment demands understanding of not just the metabolomics
phenotypes, but the genomic signals/pathways that drive these phenotypes. We performed
cytokine arrays to identify factors induced in coculture that could explain the shift to greater
glucose uptake. Having observed large fold changes in HGF secretion, we conducted a
literature search that suggested GLUT1 expression is downstream of HGF-cMET signaling
in liver and muscle (53, 54). Therefore, we hypothesized that the same pathway may be
active in breast cancer. Previous literature shows a role for HGF/cMET in breast cancer
aggressiveness. MET receptor protein tyrosine kinase regulates cell motility and invasion
(55, 56) and is stimulated by HGF (57, 58). Together, the HGF-MET pathway has been
shown to regulate stromal-epithelial interactions in multiple cancers (59-63). In breast
cancer, HGF/c-MET signaling promotes tumorigenesis (64), increases metastasis (65, 66),
and mediates drug resistance in most aggressive breast cancers (67-69). Our results
demonstrate that HGF regulates GLUT1 expression, which in turn regulates glucose uptake.
Inhibition of exogenous HGF completely blocks GLUT1 expression and decreased glucose
uptake. Given the success of small molecule inhibitors of c-MET in the clinic, the HGF/c-
MET pathway may also be a target for the regulation of tumor cell metabolism.
In summary, reciprocal interactions between cancer epithelial cells and the surrounding
microenvironment have an established impact on tumor growth (5, 6, 46) and a broad range
of other metabolic and signaling processes (26, 43, 70). Previous studies by Lisanti et al.
have shown extensive evidence in vitro for the stromal role in Warburg metabolism through
matrix remodeling (2), stromal autophagy (11), and stromal-epithelial lactate exchange (71).
Our results further demonstrate that both fibroblast and epithelial characteristics modulate
specific metabolic phenotypes in vitro and pairs one of these changes, glucose uptake, with
specific targetable gene expression changes (HGF/GLUT1). This study demonstrates that
integration of multiple data types in human tumor studies, together with in vitro
experimental studies that dissect heterotypic interactions, can yield important advances in
understanding the complex metabolic and genomic interactions during tumor evolution.
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Evolutionary theories of cancer argue that tumors must adapt to their local
microenvironments to progress, including adaptation to limited oxygen and nutrients.
While evolution of breast cancers appears to result in distinct genomic subtypes, the
corresponding metabolomic subtypes have not been well characterized. We provide
evidence that metabolomic characteristics of tumors are a result of complex interactions
between stromal and cancer cells, with stroma-epithelial interactions playing a critical
role in substrate metabolism observed in tumors. More aggressive cancers possess a
distinct metabolic phenotype, which is weakly associated with cancer subtype, and more
strongly associated with expression of a stroma-derived wound response signature.
Several studies have suggested that metabolic phenotypes of tumors may be targetable to
inhibit tumor growth, but an understanding of the genomic controls upon tissue
metabolism is needed. We demonstrate that glucose uptake in epithelial cells, occurs
partially through GLUT1 receptor. Epithelial GLUT1 expression, in turn, is dependent
upon coculture-derived HGF secretion. Because HGF/c-MET pathway is implicated in
other malignancies and c-MET inhibitors are already clinically available, blocking c-
MET response to HGF may be a plausible strategy for targeting tumor metabolism.
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Figure 1. Unsupervised cluster analysis of 379 metabolites resulted in two main clusters (Clusters
1 and 2)
(A). Cluster 1 (blue lines in dendrogram) included less aggressive tumor types or normal
breast samples, while Cluster 2 (red lines in dendrogram) included more aggressive tumors
and metastases (B, colored bars). Clusters of metabolites in the heatmap (C) implicated
hallmark Warburg phenotypes in aggressive tumors: elevated levels of amino acids, nucleic
acids, and decreased steady state levels of sugars/carbohydrates and citric acid cycle
metabolites. Pearson correlation of tumor gene expression with a previously published
wound response signature shows a role for stromal activation in Cluster 2; that is, metabolic
class was strongly correlated with expression of an in vivo wound response signature (25)
(D).
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Figure 2. Principal Component Analysis reveals a separation of tumor phenotype by key
metabolite groups
Four classes of metabolites – (A) amino acids, (B) nucleic acids, (C) tricarboxylic acid
(TCA) cyclemetabolites, and (D)carbohydrates/sugars – distinguish normal breast tissue
samples, tumors in the less aggressive metabolite cluster (Cluster 1), tumors in the more
aggressive metabolite cluster (Cluster 2), and metastatic tumors.
Brauer et al. Page 20













Figure 3. Schematic representing major metabolic pathways in the Warburg effect and their
relative levels in distinct groups of breast tumors
Red boxes indicate an increase in metabolite levels in Cluster 2 compared to the less
aggressive Cluster 1, while a green box indicates decreasing levels. The dotted red box
indicates marginally increased metabolite levels. Glucose processing through glycolysis to
pyruvate and lactate provides ATP, while the pentose phosphate shunt (PPS) generates key
intermediates in nucleotide biosynthesis. Glucose-derived citrate is exported to the cytosol
to contribute to lipid production. Glutamine is converted into glutamate and is transported to
the mitochondria where it is de-aminated to generate α-ketoglutarate, an intermediate in the
TCA cycle. Aromatic amino acids (Aromatic AAs); oxaloacetate (OAA); Acetyl coenzyme
A (Acetyl CoA); Succinyl coenzyme A (Succinyl CoA).
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Figure 4. Glucose metabolism is regulated by aggressiveness of both tumor and stroma
Glucose uptake is increased by basal-like CAFs (BCAFs). SUM149 cells had higher levels
of glucose uptake than MCF7 cells in coculture regardless of fibroblast type (A). Glucose
oxidation was suppressed in luminal cocultures (MCF7 or LCAF), while SUM149 cells
cocultured with BCAFs had increased glucose oxidation (B). Finally, analysis of glycogen
synthesis (C) revealed an increase in all coculture conditions relative to monocultures, with
the strongest fold change among basal-like breast cancer cells (SUM149). All fold change
values are expressed relative to the expected levels based on coculture composition and
monoculture metabolism, as described in Methods.
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Figure 5. HGF-dependent regulation of GLUT1 expression in breast cancer
HGF protein expression is elevated in coculture (cc) models compared to monocultures of
RMF, MCF7 and SUM149 cells(A). Cytokine arrays identify HGF as a key factor
significantly induced in coculture for both luminal and basal-like breast cancer cells (B),
when blocked using an HGF neutralizing antibody (α-HGF), the GLUT1 receptor is
inhibited at the RNA level (C). Levels of glucose uptake decrease by 66% (p=0.055) in
SUM149 cells when HGF is inhibited using antibody (D).
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